Adoption of a Cost-Saving Innovation

Germany, UK and Simvastatin

Published in: England and Germany in Europe – What Lessons Can We Learn from Each Other? / Klusen, N., Verheyen, F, and Wagner, C. Beiträge zum Gesundheitsmanagement, 32 (Baden-Baden, Germany : Nomos Verlag, 2011), Chapter 1, p. 11-26

Posted on RAND.org on January 01, 2011

by Thomas McGuire, Sebastian Bauhoff

Read More

Access further information on this document at j.mp

This article was published outside of RAND. The full text of the article can be found at the link above.

We examine how the UK and German health care systems responded to a major cost-saving innovation: the availability of generic simvastatin, a cholesterol-lowering drug. In the German Social Health Insurance, the generic's entry reduced sales volumes for both branded simvastatin (Zocor) and a close substitute, branded atorvastatin (Lipitor/Sortis). In UK, only the sales of branded simvastatin fell whereas the sales of atorvastatin were mostly unaffected. We trace these experiences to institutional differences in the two health care systems and to the structure of patient cost-sharing in particular.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.